The effects of a novel calcium-free lactate buffered dialysis and substitution fluid for regional citrate anticoagulation--prospective feasibility study
Language English Country Switzerland Media print-electronic
Document type Journal Article, Observational Study, Research Support, Non-U.S. Gov't
PubMed
25591617
DOI
10.1159/000369956
PII: 000369956
Knihovny.cz E-resources
- MeSH
- Anticoagulants administration & dosage adverse effects therapeutic use MeSH
- Energy Metabolism drug effects MeSH
- Glucose adverse effects therapeutic use MeSH
- Hemodiafiltration MeSH
- Hemodialysis Solutions adverse effects chemistry therapeutic use MeSH
- Hemofiltration * MeSH
- Cross-Over Studies MeSH
- Blood Glucose analysis MeSH
- Lactates blood MeSH
- Lactose adverse effects therapeutic use MeSH
- Drug Interactions MeSH
- Middle Aged MeSH
- Humans MeSH
- Drug Substitution MeSH
- Magnesium Deficiency chemically induced prevention & control MeSH
- Prospective Studies MeSH
- Buffers MeSH
- Renal Insufficiency blood therapy MeSH
- Aged MeSH
- Oxygen Consumption drug effects MeSH
- Feasibility Studies MeSH
- Check Tag
- Middle Aged MeSH
- Humans MeSH
- Male MeSH
- Aged MeSH
- Female MeSH
- Publication type
- Journal Article MeSH
- Observational Study MeSH
- Research Support, Non-U.S. Gov't MeSH
- Names of Substances
- Anticoagulants MeSH
- Glucose MeSH
- Hemodialysis Solutions MeSH
- Blood Glucose MeSH
- Lactates MeSH
- Lactose MeSH
- Buffers MeSH
BACKGROUND: Testing metabolic effects of a novel calcium-free, magnesium, phosphate and lactate containing solution (Lactocitrate) in combination with citrate anticoagulation. METHODS: Patients on CRRT (2,000 ml/h, blood flow (Qb) 100 ml/min, trisodium citrate (4% TSC)) with arterial lactate <3 mmol/l were included. At start, bicarbonate-buffered fluid was changed to Lactocitrate and the substitution of magnesium and phosphorus ceased. At 9 h the Qb was increased to 150 ml/min. At 18 h the CRRT dosage was increased to 3,000 ml/h. RESULTS: In 22 CVVHDF patients and another 23 on CVVH the pH, aHCO3 and Na (all p > 0.05) showed no significant changes regardless of the increased dosage of 4% TSC at 9 h (p < 0.001). Mgtot and phosphorus stabilised within normal range. Arterial lactate increased to 1.9 (1.6-2.6) mmol/l at 3,000 ml/h, p < 0.001). Citrate- and lactate-related energetic gains were up to 74 (61-86) kJ/h. CONCLUSIONS: The fluid performed well within ordinary CRRT dosage and Qb up to 150 ml/min. Lactate levels mildly increased and no magnesium and phosphorus replenishments were necessary.
References provided by Crossref.org